Frontiers in Microbiology (Jul 2024)
QcrC is a potential target for antibody therapy and vaccination to control Campylobacter jejuni infection by suppressing its energy metabolism
- Koji Hosomi,
- Koji Hosomi,
- Noritoshi Hatanaka,
- Noritoshi Hatanaka,
- Noritoshi Hatanaka,
- Atsushi Hinenoya,
- Atsushi Hinenoya,
- Atsushi Hinenoya,
- Jun Adachi,
- Yoko Tojima,
- Yoko Tojima,
- Mari Furuta,
- Mari Furuta,
- Keita Uchiyama,
- Keita Uchiyama,
- Makiko Morita,
- Makiko Morita,
- Takahiro Nagatake,
- Takahiro Nagatake,
- Azusa Saika,
- Azusa Saika,
- Soichiro Kawai,
- Soichiro Kawai,
- Ken Yoshii,
- Ken Yoshii,
- Saki Kondo,
- Saki Kondo,
- Shinji Yamasaki,
- Shinji Yamasaki,
- Shinji Yamasaki,
- Jun Kunisawa,
- Jun Kunisawa,
- Jun Kunisawa,
- Jun Kunisawa,
- Jun Kunisawa,
- Jun Kunisawa,
- Jun Kunisawa,
- Jun Kunisawa,
- Jun Kunisawa
Affiliations
- Koji Hosomi
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Koji Hosomi
- Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Noritoshi Hatanaka
- Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan
- Noritoshi Hatanaka
- Asian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan
- Noritoshi Hatanaka
- Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan
- Atsushi Hinenoya
- Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan
- Atsushi Hinenoya
- Asian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan
- Atsushi Hinenoya
- Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan
- Jun Adachi
- Laboratory of Proteomics for Drug Discovery, NIBIOHN, Osaka, Japan
- Yoko Tojima
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Yoko Tojima
- Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Mari Furuta
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Mari Furuta
- Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Keita Uchiyama
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Keita Uchiyama
- Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Makiko Morita
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Makiko Morita
- Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Takahiro Nagatake
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Takahiro Nagatake
- Laboratory of Functional Anatomy, Department of Life Sciences, School of Agriculture, Meiji University, Kawasaki, Japan
- Azusa Saika
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Azusa Saika
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore
- Soichiro Kawai
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Soichiro Kawai
- Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Ken Yoshii
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Ken Yoshii
- Graduate School of Medicine, Osaka University, Osaka, Japan
- Saki Kondo
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Saki Kondo
- Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Shinji Yamasaki
- Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan
- Shinji Yamasaki
- Asian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan
- Shinji Yamasaki
- Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan
- Jun Kunisawa
- Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Jun Kunisawa
- Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- Jun Kunisawa
- Graduate School of Medicine, Osaka University, Osaka, Japan
- Jun Kunisawa
- 0Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
- Jun Kunisawa
- 1Graduate School of Dentistry, Osaka University, Osaka, Japan
- Jun Kunisawa
- 2Graduate School of Science, Osaka University, Osaka, Japan
- Jun Kunisawa
- 3International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Jun Kunisawa
- 4Department of Microbiology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
- Jun Kunisawa
- 5Research Organization for Nano and Life Innovation, Waseda University, Tokyo, Japan
- DOI
- https://doi.org/10.3389/fmicb.2024.1415893
- Journal volume & issue
-
Vol. 15
Abstract
IntroductionCampylobacter spp. are a public health concern, yet there is still no effective vaccine or medicine available.MethodsHere, we developed a Campylobacter jejuni-specific antibody and found that it targeted a menaquinol cytochrome c reductase complex QcrC.ResultsThe antibody was specifically reactive to multiple C. jejuni strains including clinical isolates from patients with acute enteritis and was found to inhibit the energy metabolism and growth of C. jejuni. Different culture conditions produced different expression levels of QcrC in C. jejuni, and these levels were closely related not only to the energy metabolism of C. jejuni but also its pathogenicity. Furthermore, immunization of mice with recombinant QcrC induced protective immunity against C. jejuni infection.DiscussionTaken together, our present findings highlight a possible antibody- or vaccination-based strategy to prevent or control Campylobacter infection by targeting the QcrC-mediated metabolic pathway.
Keywords
